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Targeting FGFR, Ephrins, Mer, MET, and PDGFR- in
Non-small Cell Lung Cancer
Jonathan W. Riess, MD, and Joel W. Neal, MD, PhD
Following the success of endothelial growth factor receptor(EGFR) tyrosine kinase inhibitors in treating patients with
tumors harboring activating EGFR mutations, researchers are
focusing their attention on multiple other tyrosine kinase
receptors as potential druggable targets in non-small cell lung
cancer (NSCLC). Herein, we present a summary of presen-
tations for targeted therapeutics in development directed
against fibroblast growth factor receptor (FGFR), Ephrin,
Mer, PDGFR-alpha, and MET.
Summary of Presentations
FGF/FGFR
The FGFR is a membrane-bound tyrosine kinase that
binds to FGF, leading to activation of downstream growth
and survival signals in normal and tumor cells. Dr. Heasley
opened the session discussing the role of the FGFR pathway
in cancer with a focus on NSCLC. She reviewed relevant
preclinical data on the FGFR family. Gene expression array
data noted coexpression of distinct FGF and FGFRs in
various NSCLC cell lines.1 There is evidence of an autocrine
FGF-FGFR signaling loop with FGFR1 IIIc and/or FGFR2
IIIc with FGF2 and FGF9 undergoing coselection and signal
transduction.
FGFR seems to be particularly important in NSCLC of
squamous histology, because FGFR1 amplification on SNP
arrays was noted on 9.7% (15/155) squamous cell tumor
samples and 1% (6/581) of nonsquamous tumors. FISH on
the squamous cell tumor samples confirmed FGFR1 ampli-
fication in 22% of patients.2 In NSCLC cell lines carrying
amplified FGFR1, knockdown of FGFR1 and FGFR1 inhi-
bition with a small-molecule inhibitor (PD173974) led to cell
death.
AV369/AV269b/AV370
Dr. Weng discussed two monoclonal antibodies to
FGFR2 and one monoclonal antibody to FGFR3 in preclini-
cal development. AV369 is a human antibody to FGFR2
isoform IIIb and IIIc isolated by phage display, and AV369b
is a humanized antibody to isoform IIIb only. Administration
of AV369b inhibited growth of human cancer xenografts.3
AV370, a FGFR3 monoclonal antibody binding to the IIIb
and IIIc isoforms, also shows tumor inhibition in human
cancer xenografts including NSCLC.
AZD4547
Dr. Kim presented work on AZD4547, an inhibitor of
FGFR1, FGFR2, and FGFR3. Preclinical data including
gastric cancer cell lines with FGFR2 amplification indicate
that genetic modification of FGFR via amplification, trans-
location, and mutation sensitize cells to AZD4547. Phase I
dose-finding studies with AZD4547 are in progress
(NCT00979134.)
Foretinib (GSK1363089)
Dr. Ottesen presented the data on foretinib, a multiki-
nase MET inhibitor targeting MET, RON, AXL, and VEG-
FRs. MET amplification confers resistance to EGFR tyrosine
kinase inhibitors. Also, MET activation by HGF induces
resistance to EGFR tyrosine kinase inhibitors in EGFR-
mutated lung cancer cell lines. Synergistic inhibition com-
bining erlotinib and foretinib has been shown in NSCLC cell
lines with coactivation of EGFR and MET4 that is potentially
mediated by Axl up-regulation. In clinical studies, an unusual
adverse event of night blindness was noted in 3.1% of
patients treated with foretinib. The most frequent adverse
events were nausea, vomiting, fatigue, hypertension, and
diarrhea. A phase I/II study of erlotinib and foretinib in
relapsed/refractory locally advanced and metastatic NSCLC
is recruiting patients (NCT01068587). Patients with EGFR
mutant and EGFR mutation unknown status are eligible.
Ephrins
Dr. Salgia talked about the role of Ephrins in lung
cancer with a particular emphasis on EphA2. Eph receptors
are involved in embryonic developmental processes, neuronal
plasticity, and tumor growth. In tumors, Eph receptors pro-
mote cell proliferation, motility, metastases, and angiogene-
sis. Eph receptors are divided into EphA and EphB based on
structural homology and ligand-binding affinity. There are 16
known Eph receptors (10 EphA and 6 Eph B). EphA2
expression is increased in several tumor types. In lung cancer,
expression is greater in NSCLC than SCLC, and expression
in squamous histology is more than in adenocarcinoma his-
tology. Interestingly, EphA2 expression was found to be
higher in brain metastases than in primary lung tumors.5
In EphA2, a G391R mutation was identified in 2 of 28
squamous cell tumor samples and 1 of 13 lung cancer cell
lines. No mutations were identified in adenocarcinoma (0/18)
or large cell carcinoma (0/8) subtypes. EphA2 G391R causes
constitutive activation of EphA2 with increased phosphory-
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lation of Src, cortactin, and p130(Cas). Preclinical studies
indicate that EphA2 may cause increased invasiveness and
migration of tumor cells. mTOR phosphorylation was in-
creased in EphA2-mutant G391R cells with increased cell
survival, and these cells exhibited increased sensitivity to
rapamycin.6
Dasatinib inhibits multiple tyrosine kinase receptors
including activity against Src/Abl and EphA2.7 Several eph-
rin inhibitors are in preclinical development. These include
an antibody-drug conjugate (MEDI-547) composed of a fully
human monoclonal antibody against both human and murine
EphA2 and the tubulin polymerization inhibitor monomethy-
lauristatin,8 other anti-EphA2 antibodies (MEDI-531 and
MEDI-544; MedImmune, Gaithersburg, MD), an agonistic
antibody,9 Ephrin A1-targeted nanoshells,10 and small-mole-
cule inhibitors.11
Mer
Mer is a receptor tyrosine kinase involved in platelet
aggregation, cytokine secretion, and apoptotic cell clearance.
Dr. Linger began her talk by noting that the Mer tyrosine
kinase is overexpressed in NSCLC tumors and cell lines. She
highlighted that abnormal Mer expression and activation may
contribute to increased cell survival and that shRNA knock-
down of Mer confers susceptibility to apoptosis through
serum starvation. Mer knockdown also increased chemosen-
sitivity to platinum agents.
Anti-Mer monoclonal antibody treatment reduces total
cellular expression and surface expression of Mer. In cell
lines, it also reduces survival signaling, promotes apoptosis,
and increases cell death in conjunction with platinum treat-
ment. Therapeutic opportunities targeting Mer in the tumor
microenvironment are being explored.12
IMC 3G3
PDGFR- is a growth factor receptor that has roles in
tumor cells, causing transformation, progression, and metas-
tasis, as well as in the tumor microenvironment, causing
fibroblast activation and angiogenesis. Dr. Gerber spoke
about IMC 3G3, a fully human anti-PDGFR-alpha monoclo-
nal antibody. He noted the dual tumor and stromal functions
of PDGFR-alpha that complicate its preclinical assessment.13
To address this, species-specific antibodies to PDGFR-alpha
help to elucidate its tumor cell/stromal interaction. Antihu-
man IMC 3G3 targets tumor PDGFR-alpha and antimouse
IMC 1E10 targets stromal PDGFR-alpha in a mouse xeno-
graft model.
IMC 3G3 binds PDGFR-alpha with a Kd of 0.04 nM. It
inhibits PDGFR-alpha-induced activation of downstream ef-
fector molecules such as P-MAPK and P-Akt in tumor cells
and enhances the effect of chemotherapy in sarcoma xeno-
grafts. Phase I testing of IMC 3G3 noted no dose-limiting
toxicities and was generally well tolerated. A phase II trial is
recruiting participants in first-line stage IIIB/IV NSCLC. This
trial combines IMC 3G3 with carboplatin and paclitaxel with
a primary end point of PFS and crossover permitted at
progression (NCT00918203.)
MEDI-575
Dr. Bradley spoke about MEDI-575, a novel fully
human antibody to PDGFR-alpha. Highlighting MEDI-575’s
effect on the tumor microenvironment, Dr. Bradley showed
mouse model NSCLC data of inhibition of tumor growth
when hPDGFR-alpha is expressed only in the stroma. Phase
I single-agent trials noted no DLT. A phase II trial began
enrollment in March 2011 combining MEDI-575 with carbo-
platin and paclitaxel in untreated stage IIIB/IV NSCLC pa-
tients (NCT01268059.)
Future Directions
Although all these targets have inhibitors in develop-
ment, the potential clinical benefit of targeting these path-
ways in NSCLC is still being established.
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